

TECHNICAL SHEET IDYLLA™ ctKRAS MUTATION ASSAY



The **Idylla™ ctKRAS Mutation Assay**, performed on the Biocartis Idylla™ System, is an assay for the qualitative detection of 21 mutations in **codons 12, 13, 59, 61, 117 and 146** of the *KRAS* gene. The Idylla™ ctKRAS Mutation Assay extracts and amplifies *KRAS* circulating tumor DNA (ctDNA) from 1 ml of plasma. The Assay is a **sample-to-result** real-time PCR, intended to use for research applications only.

FEATURES

ctKRAS mutation detection		
Codon 12 (exon2)	G12C	(c.34G>T)
	G12R	(c.34G>C)
	G12S	(c.34G>A)
	G12A	(c.35G>C)
	G12D	(c.35G>A)
	G12V	(c.35G>T)

Codon 13 (exon2)	G13D	(c.38G>A)

Codon 59 (exon3)	A59E	(c.176C>A)
	A59G	(c.176C>G)
	A59T	(c.175G>A)

Codon 61 (exon 3)	Q61K	(c.181C>A; c.180_181delinsAA)
	Q61L	(c.182A>T)
	Q61R	(c.182A>G)
	Q61H	(c.183A>C; c.183A>T)

Codon 117 (exon 4)	K117N	(c.351A>C; c.351A>T)

Codon 146 (exon 4)	A146P	(c.436G>C)
	A146T	(c.436G>A)
	A146V	(c.437C>T)

KRAS Total (acting as Sample Processing Control)

Specimen requirements

Sample Type 1 ml of plasma

Supported blood collection tubes

EDTA tubes Blood must be centrifuged within 4 hours after collection

Cell-free DNA BCT® tubes (Streck) Blood must be centrifuged within 3 days after collection

Total turnaround time

Time Approx. 130 minutes

Result Reporting

Report Qualitative genotype call

IDYLLA™ ctRAS PUBLICATIONS

Check our website: <https://www.biocartis.com/publications/articles-posters?cat=19> and subscribe to receive our newest publications.



Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and the Idylla trademark and logo are used trademarks owned by Biocartis. Idylla™ platform is CE-marked IVD in Europe. Idylla™ ctKRAS Mutation Assay is available for Research Use Only (RUO), not for use in diagnostic procedures. Idylla™ is available for sale in EU, USA and some other countries. Please check availability with the local Biocartis sales representative.